Drug intelligence / Profile preview

Revilon

Development stage: Unknown
Lead developer: Celon Pharma
Administration: Intravenous, Intramuscular, Parenteral

Overview

Revilon is a brand name used by Celon Laboratories to designate its Critical Care division and product portfolio. Established in 2009, the Revilon line encompasses a wide range of generic pharmaceutical products specifically intended for use in intensive care units (ICU) and emergency medical settings. The portfolio includes various therapeutic categories such as high-end injectable antibiotics (e.g., meropenem, colistimethate), antifungals (e.g., caspofungin), and other life-saving medications. Revilon does not refer to a single drug molecule but rather serves as a commercial umbrella for Celon's critical care offerings, all of which are approved generic drugs manufactured by the company.

Brand names: Revilon

Beyond the preview

Go deeper on Revilon.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revilon.

Explore the full profile